TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03607110

Intervention type: DRUG
Intervention: Ketamine
Description: sedation drugs

Intervention type: DRUG
Intervention: fentanyl
Description: sedation drugs

Intervention type: DEVICE
Intervention: patient control analgesia
Description: patient control analgesia

Intervention type: DEVICE
Intervention: patient control analgesia
Description: patient control analgesia
Study: NCT00661687

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Currently Marketed PureVision Contact Lens.
Description: Contact lens for continuous wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternate Design of the PureVision Contact Lens.
Description: Contact lens for continuous wear
Study: NCT05308719

Intervention type: DEVICE
Group type: OTHER
Intervention: High Flow Nasal Therapy
Description: High Flow Nasal Oxygen (Airvo2 Device)
Study: NCT00912509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin
Description: riboflavin 0.1% is applied every 2 minutes for 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVX Light
Description: UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVX Light
Description: UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
Study: NCT01234376

Intervention type: DEVICE
Intervention: Confocal laser endomicroscopy
Description: Confocal laser endomicroscopy

Intervention type: DEVICE
Intervention: Confocal laser endomicroscopy
Description: Confocal laser endomicroscopy
Study: NCT00586066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator. Placebo-matching memantine tablet.
Study: NCT01131767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium & Pseudoephedrine HCl
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium & Pseudoephedrine HCl
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Study: NCT02837952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDC IBU/APAP 250 mg/500 mg
Description: FDC IBU/APAP 250 mg/500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02908243

Intervention type: OTHER
Intervention: collection of baseline data
Description: collection of baseline data including ages, types, severity, inhibitors and comorbidities
Study: NCT00935207

Intervention type: OTHER
Intervention: Pediatric Pain Diary
Description: Pain diary designed for pediatric patients
Study: NCT00003907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
Study: NCT02450188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
Study: NCT01177306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release guanfacine
Description: 1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
Study: NCT02450188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBST
Description: The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
Study: NCT01223638

Intervention type: OTHER
Intervention: Audiometry
Description: Audiometry
Study: NCT01557569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
Study: NCT02366858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 19 gauge
Description: Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 19 gauge
Description: Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge
Description: Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
Study: NCT00389727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT05063890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Specific Post Isometric Relaxation MET
Description: 3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Movement Specific Post Isometric Relaxation MET
Description: 3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral postero-anterior glide
Description: 3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral postero-anterior glide
Description: 3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heating and TENS
Description: Heating and TENS for 10 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heating and TENS
Description: Heating and TENS for 10 minutes
Study: NCT01516229

Intervention type: DRUG
Intervention: somatropin
Description: Prescription of somatropin at the discretion of the physician
Study: NCT00959712

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ECA Interaction
Description: The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
Study: NCT03003962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: Anti-PD-L1 monoclonal Antibody monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + carboplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + cisplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + carboplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + cisplatin
Description: Chemotherapy Agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + carboplatin
Description: Chemotherapy Agent
Study: NCT02322021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
Study: NCT02618629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Z-215
Description: Single oral dose of 20mg Z-215 and 14C-Z-215 solution
Study: NCT02121704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Endoscope Imaging (Scope Guide)
Study: NCT03356015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4L Polyethylene Glycol
Description: 4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3L Polyethylene Glycol
Description: 3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
Study: NCT03905135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
Study: NCT04002362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) will be administered deep in the gluteal muscle by a trained registered nurse.
Study: NCT02783183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YHD1119
Description: 2 by 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119
Description: 2 by 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: 2 by 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica
Description: 2 by 2
Study: NCT01639443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Predictive no-show overbooking
Description: During intervention period, every Veteran scheduled for an endoscopy will be offered fast-track offer, which gives them a chance to get their endoscopy procedure done earlier than usual scheduling by overbooking their appointment in a predictive no-show slot.
Study: NCT03563781

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel node detection
Description: Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
Study: NCT00490555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 10 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 10 g
Study: NCT01358253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
Study: NCT02322021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
Study: NCT01358253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
Study: NCT01702571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
Study: NCT03438318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
Study: NCT01358253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-Mercaptopurine
Description: Maintenance:60mg/m2 daily for 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Maintenance:60mg/m2 daily for 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
Study: NCT04649749

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI scan

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI scan

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI scan
Study: NCT00993473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: 100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~* Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~* Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~* Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~* HbA1c \<7.5%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Protamine Hagedorn (NPH) insulin
Description: NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine
Study: NCT03438318

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
Study: NCT00993473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
Study: NCT01202357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Case Management
Description: Community case management for psychosis by designated key-worker according to specified protocol

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Community Case Management
Description: Community case management for psychosis by designated key-worker according to specified protocol
Study: NCT03020316

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Mentor
Description: A volunteer with a similar disease as the subject

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Mentor
Description: A volunteer with a similar disease as the subject

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcendental Meditation
Description: A meditation technique